RP-54745 is a potent and selective antagonist of the leukotriene D4 (LTD4) receptor, making it a valuable tool in the study of inflammatory pathways, particularly in asthma and other respiratory diseases. It has been used in preclinical research to block the bronchoconstrictive effects of cysteinyl leukotrienes, which play a key role in airway inflammation and hyperresponsiveness. By inhibiting LTD4-mediated responses, RP-54745 helps elucidate the contribution of leukotriene signaling in allergic reactions and supports the development of targeted anti-inflammatory therapies. Its application is primarily confined to experimental models for investigating asthma pathophysiology and evaluating potential therapeutic interventions.